{"result": {"id": "chatcmpl-805", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "Brolucizumab is a medication currently under study for treating various eye conditions, including certain forms of age-related macular degeneration (AMD). It is an anti-VEGF antibody that helps manage neovascular AMD, a condition where abnormal blood vessels grow in the retina. Brolucizumab can also be used to treat wet AMD and retinal diseases.  It is often referred to as IB and has been used to treat central serous retinopathy (CSR) secondary to autoimmune diseases such as uveitis or ankylosing spondylitis. \n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743161801, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 110, "prompt_tokens": 312, "total_tokens": 422, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are a helpful assistant responsible for generating a comprehensive summary of the data provided below.\nGiven one or two entities, and a list of descriptions, all related to the same entity or group of entities.\nPlease concatenate all of these into a single, comprehensive description. Make sure to include information collected from all the descriptions.\nIf the provided descriptions are contradictory, please resolve the contradictions and provide a single, coherent summary.\nMake sure it is written in third person, and include the entity names so we have the full context.\n\n#######\n-Data-\nEntities: \"BROLUCIZUMAB\"\nDescription List: [\"Brolucizumab is a drug currently under study for treating certain eye conditions. It is also being investigated as a potential treatment for inflammation in the eye, specifically for conditions like neovascular age-related macular degeneration (nAMD).  This medication is often referred to as IB and has been used to treat central serous retinopathy (CSR) secondary to autoimmune diseases such as uveitis or ankylosing spondylitis. \\n\", \"Brolucizumab is a medication used in the treatment of neovascular age-related macular degeneration (nAMD). It is an anti-VEGF antibody that helps manage this condition. Brolucizumab can also be used to treat wet age-related macular degeneration and retinal diseases.  It is classified as a medication, and it is often included in treatment regimens for these conditions. \\n\"]\n#######\nOutput:\n", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 500, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_summarize_e5e8d58b35f4778e26ad198fa1095b88d9172ea971bb24ea36a248899953d783_v2"}